Dynavax Technologies (NASDAQ:DVAX) Upgraded at StockNews.com

StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a hold rating to a buy rating in a report released on Monday morning.

A number of other analysts have also commented on the stock. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Trading Up 2.1 %

NASDAQ:DVAX opened at $13.69 on Monday. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of 76.06 and a beta of 1.32. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.05. The business’s 50-day moving average price is $12.84 and its two-hundred day moving average price is $12.07. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The firm had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. On average, equities analysts expect that Dynavax Technologies will post 0.32 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in Dynavax Technologies in the fourth quarter valued at approximately $35,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Dynavax Technologies by 37.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 420,325 shares of the biopharmaceutical company’s stock valued at $5,368,000 after purchasing an additional 113,872 shares during the last quarter. Woodline Partners LP increased its position in shares of Dynavax Technologies by 2.2% during the fourth quarter. Woodline Partners LP now owns 794,475 shares of the biopharmaceutical company’s stock worth $10,145,000 after buying an additional 17,156 shares during the period. Squarepoint Ops LLC raised its stake in Dynavax Technologies by 509.3% during the fourth quarter. Squarepoint Ops LLC now owns 124,807 shares of the biopharmaceutical company’s stock worth $1,594,000 after buying an additional 104,325 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in Dynavax Technologies by 9.0% during the fourth quarter. Two Sigma Investments LP now owns 866,356 shares of the biopharmaceutical company’s stock valued at $11,063,000 after acquiring an additional 71,575 shares during the last quarter. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.